14 matches for your search in the start-up spotlight
rss
05-May-2025
A record number of over 320 innovators from the international life-science community gathered in Munich for the 17th BioVaria, Europe’s premier event for showcasing commercially attractive inventions and start-ups. A highlight was the BioVaria Startup Pitch & Partner Program, where 10 handpicked ...
Among the GO-Bio initial and ForTra projects, Innovade, Cognisa and Mallia Therapeutics were selected as winners
07-May-2024
The international life-science community gathered last week in Munich for the 16th BioVaria, Europe’s leading showcasing event for breakthrough technologies and start-ups in the field. Organized by 13 technology transfer organizations, the event serves as a catalyst for forging partnerships ...
22-Jun-2022
Aconsortium of strong partners has launched the CARMA FUND I as a new vehicle for the translation of promising early-stage life-science projects: the initiators, Ascenion GmbH, a life-science focused technology transfer company of the LifeScience Foundation and the Goethe-University, Frankfurt ...
17-May-2022
This year’s hybrid BioVaria brought together over 230 life-science innovators – most of them live in Munich – boosting academia–industry partnering. Following two years of mainly virtual interaction, the event was well received by investors and decision makers from industry as well as academic ...
Start-up pursues a unique approach for the treatment
27-Aug-2021
Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMed Partners, ...
Initiation of the IMAGE1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in Q4 2021
05-Aug-2021
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with ...
New platform for developing therapeutic antibodies against cancer and new approach to the development of drugs for Parkinson’s disease
04-May-2021
This year’s virtual BioVaria from 26 to 28 April brought together 250 life-science innovators to hear about the most exciting technologies and start-ups to emerge from publicly funded European research, and to initiate partnerships between science and business. With 75 licensable projects and 16 ...
Aignostics Raises €5 Million Seed Round
31-Aug-2020
Aignostics, a spin-off from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) pioneering computational pathology for pharmaceutical research and diagnostics, has announced the closing of a €5 M seed round funding. Boehringer Ingelheim Venture Fund (BIVF) led the round, ...
T-knife’s proprietary humanized mouse platform (HuTCR) T-cell Receptors expected to provide superior affinity/specificity properties
10-Aug-2020
T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, announced the closing of a €66 M Series A round of financing. The round was led by Versant Ventures and RA Capital Management, with significant ...
Ascenion's Portfolio Company WBC Acquired by Klaria
23-Sep-2019
Ascenion GmbH, technology transfer partner of the Helmholtz Centre for Infection Research (HZI), announces the take-over of its portfolio company WBC Drug Delivery Technologies (WBC) by Klaria Pharma Holding AB in an all-stock deal. WBC was founded earlier this year to further advance a new drug ...
